You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/76144
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMaestá, Izildinha-
dc.contributor.authorGrowdon, Whitfield B.-
dc.contributor.authorGoldstein, Donald P.-
dc.contributor.authorBernstein, Marilyn R.-
dc.contributor.authorHorowitz, Neil S.-
dc.contributor.authorRudge, Marilza Vieira Cunha-
dc.contributor.authorBerkowitz, Ross S.-
dc.date.accessioned2014-05-27T11:30:05Z-
dc.date.accessioned2016-10-25T18:52:00Z-
dc.date.available2014-05-27T11:30:05Z-
dc.date.available2016-10-25T18:52:00Z-
dc.date.issued2013-08-01-
dc.identifierhttp://dx.doi.org/10.1016/j.ygyno.2013.05.017-
dc.identifier.citationGynecologic Oncology, v. 130, n. 2, p. 312-316, 2013.-
dc.identifier.issn0090-8258-
dc.identifier.issn1095-6859-
dc.identifier.urihttp://hdl.handle.net/11449/76144-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/76144-
dc.description.abstractObjective The purpose of this study was to identify the clinical factors associated with time to hCG remission among women with low-risk postmolar GTN. Methods This study included a non-concurrent cohort of 328 patients diagnosed with low-risk postmolar GTN according to FIGO 2002 criteria. Associations of time to hCG remission with history of prior mole, molar histology, time to persistence, use of D&C at persistence, presence of metastatic disease, FIGO score, hCG values at persistence, type of first line therapy and use of multiagent chemotherapy were investigated with both univariate and multivariate analyses. Results Overall median time to remission was 46 days. Ten percent of the patients required multi-agent chemotherapy to achieve hCG remission. Multivariate analysis incorporating the variables significant on univariate analysis confirmed that complete molar histology (HR 1.45), metastatic disease (HR 1.66), use of multi-agent therapy (HR 2.00) and FIGO score (HR 1.82) were associated with longer time to remission. There was a linear relationship between FIGO score and time to hCG remission. Each 1-point increment in FIGO score was associated with an average 17-day increase in hCG remission time (95% CI: 12.5-21.6). Conclusions Complete mole histology prior to GTN, presence of metastatic disease, use of multi-agent therapy and higher FIGO score were independent factors associated with longer time to hCG remission in low-risk GTN. Identifying the prognostic factors associated with time to remission and effective counseling may help improve treatment planning and reduce anxiety in patients and their families. © 2013 Elsevier Inc. All rights reserved.en
dc.format.extent312-316-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectLow-risk gestational trophoblastic neoplasia hCG remission Prognostic factors Chemotherapy-
dc.subjectchorionic gonadotropin-
dc.subjectadolescent-
dc.subjectadult-
dc.subjectcancer chemotherapy-
dc.subjectchild-
dc.subjectcohort analysis-
dc.subjectfemale-
dc.subjecthistopathology-
dc.subjecthuman-
dc.subjectmajor clinical study-
dc.subjectmetastasis-
dc.subjectpriority journal-
dc.subjectremission-
dc.subjectschool child-
dc.subjecttrophoblastic tumor-
dc.subjectChemotherapy-
dc.subjecthCG remission-
dc.subjectLow-risk gestational trophoblastic neoplasia-
dc.subjectPrognostic factors-
dc.subjectAdolescent-
dc.subjectAdult-
dc.subjectChild-
dc.subjectChorionic Gonadotropin-
dc.subjectFemale-
dc.subjectGestational Trophoblastic Disease-
dc.subjectHumans-
dc.subjectMiddle Aged-
dc.subjectPregnancy-
dc.subjectPrognosis-
dc.subjectRisk-
dc.subjectTime Factors-
dc.titlePrognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasiaen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionMassachusetts General Hospital-
dc.contributor.institutionBrigham and Women's Hospital-
dc.contributor.institutionDonald P. Goldstein M.D. Tumor Registry-
dc.contributor.institutionHarvard Cancer Center-
dc.contributor.institutionHarvard Medical School-
dc.description.affiliationDepartment of Gynecology and Obstetrics Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP-
dc.description.affiliationDepartment of Obstetrics and Gynecology Division of Gynecologic Oncology Massachusetts General Hospital, Boston-
dc.description.affiliationDepartment of Obstetrics and Gynecology Division of Gynecologic Oncology Brigham and Women's Hospital, Boston-
dc.description.affiliationNew England Trophoblastic Disease Center Donald P. Goldstein M.D. Tumor Registry, Boston-
dc.description.affiliationTrophoblastic Diseases Center Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP-
dc.description.affiliationDana Farber Cancer Institute Harvard Cancer Center, Boston-
dc.description.affiliationHarvard Medical School, Boston-
dc.description.affiliationUnespDepartment of Gynecology and Obstetrics Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP-
dc.description.affiliationUnespTrophoblastic Diseases Center Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP-
dc.identifier.doi10.1016/j.ygyno.2013.05.017-
dc.identifier.wosWOS:000322410900012-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofGynecologic Oncology-
dc.identifier.scopus2-s2.0-84880308422-
dc.identifier.orcid0000-0002-9227-832X-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.